 CAMBRIDGE, Mass., Dec. 21, 2020 GLOBE NEWSWIRE -- Evelo Biosciences, Inc. Nasdaq:EVLO, a clinical stage biotechnology company developing a new modality of orally delivered product candidates which act in the small intestine to drive systemic effects, today announced the appointment of Jonathan Zung, Ph.D., as Chief Development Officer and a member of the Evelo Executive Team. Dr. Zung is an established industry veteran, who brings more than 25 years of global pharmaceutical development and commercialization experience to Evelo. 